Li J, Wang Y, Zhang B, et al. - In lung cancer, researchers sought to determine the clinical features of mesenchymal-epithelial transition (MET) amplification as well as how subsets of patients with MET amplification identified by next-generation sequencing (NGS) responded to crizotinib. For this purpose, they gathered NGS sequencing data for patients with MET amplification from January 2018 to April 2019 in their institution. They undertook a retrospective analysis of crizotinib's effectiveness in MET amplification. The presence of primary MET amplification was found in 3.27% of 2,694 patients with lung cancer. Acquired MET amplification accounted for 16.04% of re-biopsy patients.  Longer PFS following crizotinib therapy was seen in patients with copy number greater than 4. PFS did not differ significantly between patients with primary and acquired MET amplification.